Kyle Mikson CFA, an analyst from Canaccord Genuity, maintained the Buy rating on Natera (NTRA – Research Report). The associated price target remains the same with $180.00.
Kyle Mikson CFA has given his Buy rating due to a combination of factors that highlight Natera’s strong market position and growth potential. The recent expansion of Medicare coverage for Natera’s Signatera test to include non-small cell lung cancer (NSCLC) is a significant development. This coverage, validated by independent studies, enhances Signatera’s utility in the surveillance setting and is expected to drive revenue growth and potentially lead to further commercial payer coverage.
Moreover, the robust patent protections for Signatera and its competitive positioning in the market further support the Buy rating. Despite a recent legal setback involving patent claims, the overall outlook for Signatera remains positive, with multiple potential catalysts for growth, including guideline inclusions and expanded payer coverage. These factors collectively underscore the attractive investment opportunity presented by Natera’s shares.
In another report released on February 10, Raymond James also reiterated a Buy rating on the stock with a $175.00 price target.